Skip to main content

British National Formulary November 2024 Update

This update contains 10 significant changes, 4 dose changes, 5 new monographs, and 5 new preparations.

Significant Changes:

  • Antibacterials, principles of therapy: update to notifiable diseases reporting.
  • Antibacterials, use for prophylaxis: updated guidance on secondary prevention of meningococcal disease and secondary prevention of pertussis.
  • Borderline substances: oral nutritional supplements have been re-organised in a new section called Oral nutrition.
  • Co-amoxiclav: update to structure of indications and dose section; tablet dose expression changed to co-amoxiclav (total of amoxicillin and clavulanic acid).
  • Faricimab: new indication and dose for macular oedema secondary to retinal vein occlusion.
  • Immunisation schedule: updated guidance for immunisation against influenza, and for pertussis in pregnancy.
  • Lower urinary tract symptoms in males: new guidance.
  • Oxytocin: risk of overdose during labour and childbirth [NPSA advice].
  • Pertussis vaccine: updated guidance for immunisation.
  • Topical corticosteroids: update to the list of topical corticosteroid potencies.

Dose Changes:

  • Ciprofloxacin [indication changed from prevention of secondary case of meningococcal meningitis to prevention of secondary case of meningococcal disease].
  • Lithium carbonate [update to dosing].
  • Lithium citrate [update to dosing].
  • Risankizumab [update to dosing].

New Monographs:

  • Fabhalta® [iptacopan].
  • Isoprenaline hydrochloride.
  • Mepsevii® [vestronidase alfa].
  • Obgemsa® [vibegron].
  • Yselty® [linzagolix].

New Preparations: Ceyxa® [olanzapine]; Co-amoxiclav 1 g (875/125 mg) tablet; Co-amoxiclav 2.2 g (2000/200 mg) infusion; Metalyse® 5000 units (25 mg) [tenecteplase]; Xyquila® [olanzapine].